Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 9;8:126. doi: 10.1038/s41598-017-17786-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Scn8a knockdown provides robust seizure protection in a mouse model of MTLE. (a) Representative EEG traces from two depth electrodes in the dorsal hippocampus, two cortical electrodes, and EMG before, during, and after a spontaneous seizure. (b) Percent of mice seizing during the 8 weeks of EEG analyses. Only 1/10 (10%) of shRNA-Scn8a-treated MTLE mouse developed spontaneous seizures whereas all KA-only and shRNA-scram-treated MTLE mice exhibited seizures. The data for the single shRNA-Scn8a-treated mouse that exhibited spontaneous seizures is divided by 10 to obtain the average values shown in panels c and d. (c) Number of seizures weekly was dramatically lower in shRNA-Scn8a-treated MTLE mice compared to KA only and shRNA-Scram-treated MTLE mice. (d) Average number of seizures during the 8 weeks of the EEG recording period was comparable between KA-only and shRNA-scram-treated mice. The average number of seizures in shRNA-Scn8a-treated mice was significantly lower than shRNA-scram (p < 0.05) and KA-only (p < 0.05) mice. N = 7–10/group. Non-parametric Kruskal-Wallis test followed by Dunn’s multiple comparisons test. All data are presented as mean ± SEM. *p < 0.05, ***p < 0.001, N.S, not significant.